Featuring a slide presentation and related discussion from Dr Michiel van der Heijden, including the following topics: Efficacy and safety data from the Phase III EV-302/KEYNOTE-A39 trial comparing enfortumab vedotin/pembrolizumab to chemotherapy for patients with previously untreated metastatic urothelial bladder cancer (mUBC) (0:00) Principal fin…

Featuring an interview with Dr Michiel van der Heijden, including the following topics: Underlying biological mechanisms of the bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition (0:00) Treatment patterns and survival outcomes for patients admitted to the intensive care unit due to immune-related adve…

Featuring a slide presentation and related discussion from Dr Priyanka Sharma, including the following topics: Biomarker Assays in the Identification and Prognostication of Patients with Breast Cancer (0:00) Utility of Circulating Tumor DNA in the Prognostication of Localized Breast Cancer (24:28) Treatment of HR-Positive, HER2-Negative Advanced Br…

Featuring an interview with Prof Giuseppe Curigliano, including the following topics: Counseling patients with newly diagnosed metastatic breast cancer (mBC); role of patient-reported outcomes and advocacy (0:00) Individualized selection of up-front therapy for patients with HR-positive, HER2-negative mBC (6:02) Selection and sequencing of treatmen…

Featuring an interview with Dr Angeles Alvarez Secord, including the following topics: Front-line management of ovarian cancer (0:00) Management of relapsed/refractory ovarian cancer (20:06) Management of microsatellite instability-high/mismatch repair-deficient endometrial cancer (23:20) Management of microsatellite stable/mismatch repair-proficie…

Inside the Issue: Integrating ALK-Targeted Therapy into the Management of Localized Non-Small Cell Lung Cancer | Faculty Presentation 1: Significance of Biomarker Testing in Localized Non-Small Cell Lung Cancer (NSCLC) and Historical Management Paradigm for ALK-Positive Disease — Professor Solange Peters, MD, PhD CME information and select publicat…

Inside the Issue: Integrating ALK-Targeted Therapy into the Management of Localized Non-Small Cell Lung Cancer | Faculty Presentation 2: Emerging Role and Practical Application of ALK-Targeted Therapy in Localized NSCLC — Professor Ben Solomon, MBBS, PhD CME information and select publicationsBy Dr. Neil Love

Featuring perspectives from Prof Solange Peters and Prof Ben Solomon, including the following topics: Introduction (0:00) Significance of Biomarker Testing in Localized Non-Small Cell Lung Cancer (NSCLC) and Historical Management Paradigm for ALK-Positive Disease — Prof Peters (9:17) Emerging Role and Practical Application of ALK-Targeted Therapy i…

Featuring perspectives from Dr Sara A Hurvitz, including the following topics: Case: A woman in her late 40s who received treatment for triple-negative breast cancer develops lung metastases 2 years later (0:00) Clinical trials investigating TROP2-targeting antibody-drug conjugates (13:28) Identifying and targeting HER2 in HER2 low-expressing disea…

Featuring perspectives from Dr Melissa Johnson, Dr Ticiana Leal and Dr Manish Patel, including the following topics: Introduction: Two Faces of Lung Cancer Research (0:00) B7-H3-Targeted Antibody-Drug Conjugates for Lung Cancer — Dr Patel (16:14) Potential Role of Tumor Treating Fields in the Management of Metastatic Non-Small Cell Lung Cancer — Dr…

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Multiple Myeloma | Faculty Presentation 2: Chimeric Antigen Receptor T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates for MM — Jesús G Berdeja, MD CME information and select publications…

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Multiple Myeloma | Faculty Presentation 1: Current and Emerging Therapeutic Approaches for Multiple Myeloma (MM) — Thomas Martin, MD CME information and select publicationsBy Dr. Neil Love

Featuring perspectives from Dr Jesús G Berdeja and Dr Thomas Martin, including the following topics: Introduction: Real-World Regulatory Issues in Multiple Myeloma (MM) (0:00) Newly Diagnosed MM (14:30) Novel Agents for Relapsed/Refractory MM (24:58) Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies (44:28) CME information and sele…